Results 31 to 40 of about 42,088 (274)
Atherosclerosis Plus, 2021 Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels.
Maria Giovanna Lupo +11 more
doaj +1 more source
SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. [PDF]
, 2013 The secretory pathway of eukaryotic cells packages cargo proteins into COPII-coated vesicles for transport from the endoplasmic reticulum (ER) to the Golgi.
Adams, Elizabeth +17 more
core +1 more source
Gene Therapy Targeting PCSK9 [PDF]
Metabolites, 2022 The last decades of research in cardiovascular prevention have been characterized by successful bench-to-bedside developments for the treatment of low-density lipoprotein (LDL) hypercholesterolemia. Recent examples include the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) with monoclonal antibodies, small interfering RNA and ...
Julius L. Katzmann +2 more
openaire +4 more sources
Glycaemic effects of non-statin lipid-lowering therapies [PDF]
, 2016 Since the publication of the JUPITER trial, attention has been focused on the adverse glycemic effects of statin therapy. Although the modest increase in the risk of new diabetes mellitus is outweighed by the reduction in cardiovascular events for ...
Collins, Patrick D., Sattar, Naveed
core +1 more source
Polymorphic Variant rs11206510 in PCSK9 and Risk of Coronary Artery Disease in Bulgarians
Acta Medica Bulgarica, 2023 The aim of this study was to investigate the potential association of rs11206510 in PCSK9 gene with coronary artery disease (CAD) and myocardial infarction (MI) in Bulgarians.
Tzveova R. +7 more
doaj +1 more source
Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]
, 2017 Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah +13 more
core +1 more source
Renal Failure, 2020 Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a major post-transcriptional regulator of low-density lipoprotein receptor degradation. Recently, PCSK9 was shown to be overexpressed by liver cells in rats with proteinuria.
Huaying Shen +5 more
doaj +1 more source
Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9 [PDF]
, 2017 BACKGROUND: A beneficial effect on cardiovascular risk may be obtained by improving lipid-related serum lipoprotein functions such as high-density lipoproteins (HDLs) cholesterol efflux capacity (CEC) and serum cholesterol loading capacity (CLC) and by ...
Adorni, Maria Pia +7 more
core +3 more sources
Research Models for Studying Vascular Calcification [PDF]
, 2020 Calcification of the vessel wall contributes to high cardiovascular morbidity and mortality. Vascular calcification (VC) is a systemic disease with multifaceted contributing and inhibiting factors in an actively regulated process.
Babic, Milen +4 more
core +1 more source
Cholesterol metabolism is altered in Rett syndrome: A study on plasma and primary cultured fibroblasts derived from patients [PDF]
, 2014 Rett (RTT) syndrome is a severe neurological disorder that affects almost exclusively females. Several detectable mutations in the X-linked methyl-CpG-binding protein 2 gene (MECP2) are responsible for the onset of the disease.
Di Tunno, Ilenia +6 more
core +3 more sources